Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company developing bacteriophage therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Deborah Birx, M.D. will deliver a corporate presentation on September 10, 2025, from 1:30-2:00 PM ET in New York. The company specializes in developing treatments for antibiotic-resistant and difficult-to-treat bacterial infections.
Armata Pharmaceuticals (NYSE American: ARMP), una biotech in fase clinica che sviluppa terapie a base di batteriofagi, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference. La CEO Deborah Birx, M.D. terrà una presentazione aziendale il 10 settembre 2025, dalle 13:30 alle 14:00 ET a New York. L'azienda è specializzata nello sviluppo di trattamenti per infezioni batteriche difficili da trattare e resistenti agli antibiotici.
Armata Pharmaceuticals (NYSE American: ARMP), una compañía biotecnológica en fase clínica que desarrolla terapias basadas en bacteriófagos, anunció su participación en la H.C. Wainwright 27th Annual Global Investment Conference. La directora ejecutiva Deborah Birx, M.D. ofrecerá una presentación corporativa el 10 de septiembre de 2025, de 1:30 a 2:00 PM ET en Nueva York. La empresa se especializa en el desarrollo de tratamientos para infecciones bacterianas difíciles de tratar y resistentes a los antibióticos.
Armata Pharmaceuticals (NYSE American: ARMP)는 박테리오파지(바이러스)를 이용한 치료제를 개발하는 임상 단계의 바이오테크 기업으로, 다가오는 H.C. Wainwright 27th Annual Global Investment Conference에 참가한다고 발표했습니다. CEO Deborah Birx, M.D.는 2025년 9월 10일, 오후 1:30~2:00 ET에 뉴욕에서 기업 발표를 진행합니다. 이 회사는 항생제 내성 및 치료가 어려운 세균성 감염 치료제 개발을 전문으로 합니다.
Armata Pharmaceuticals (NYSE American: ARMP), une société biotechnologique en phase clinique développant des thérapeutiques à base de bactériophages, a annoncé sa participation à la H.C. Wainwright 27th Annual Global Investment Conference. La PDG Deborah Birx, M.D. donnera une présentation d'entreprise le 10 septembre 2025, de 13h30 à 14h00 (heure ET) à New York. La société est spécialisée dans le développement de traitements pour les infections bactériennes résistantes aux antibiotiques et difficiles à traiter.
Armata Pharmaceuticals (NYSE American: ARMP), ein Biotech-Unternehmen in klinischer Entwicklungsphase, das Bakteriophagen-Therapeutika entwickelt, hat seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference angekündigt. CEO Deborah Birx, M.D. wird am 10. September 2025, von 13:30–14:00 Uhr ET in New York eine Unternehmenspräsentation halten. Das Unternehmen spezialisiert sich auf die Entwicklung von Behandlungen für antibiotikaresistente und schwer zu behandelnde bakterielle Infektionen.
- None.
- None.
Armata's presentation is scheduled for Wednesday, September 10, from 1:30-2:00 PM ET.
To schedule a one-on-one meeting, please contact your H.C. Wainwright representative.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices manufacturing to support full commercialization.
Media Contacts:
At Armata:
Pierre Kyme
ir@armatapharma.com
310-594-7035
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302540984.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
When is Armata Pharmaceuticals (ARMP) presenting at the H.C. Wainwright Conference 2025?
Who will be presenting for Armata Pharmaceuticals at the H.C. Wainwright Conference?
What type of therapeutics is Armata Pharmaceuticals (ARMP) developing?
How can investors arrange meetings with Armata Pharmaceuticals at the conference?
